Status:
UNKNOWN
Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody
Lead Sponsor:
Dalian University
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
40-80 years
Phase:
PHASE1
Brief Summary
to evaluate the prognosis of non-small cell lung carcinoma patients under CIK cellular treatment with PD-1 blocking on top of the standard therapy
Eligibility Criteria
Inclusion
- non-small cell lung cancer;
- more than 50% tumor tissues positive with PD-L1;
- EGFR and ALK wild type
- no other tumors
Exclusion
- with systematic diseases shortening survival
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03282435
Start Date
January 1 2018
End Date
January 1 2023
Last Update
September 14 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.